MARKET

HTGM

HTGM

HTG Molecular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.28
+0.19
+3.73%
After Hours: 5.28 0 0.00% 17:07 12/04 EST
OPEN
5.16
PREV CLOSE
5.09
HIGH
5.65
LOW
5.07
VOLUME
509.77K
TURNOVER
--
52 WEEK HIGH
13.80
52 WEEK LOW
3.780
MARKET CAP
25.03M
P/E (TTM)
-1.1173
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is HTG Molecular Diagnostics, Inc. (HTGM) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Insider Monkey · 5d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
Thinking about buying stock in HTG Molecular Diagnostics, Moderna, FuelCell Energy, BioNTech, or Blink Charging?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, MRNA, FCEL, BNTX, and BLNK.
PR Newswire - PRF · 11/23 13:30
HTG Announces One-for-Fifteen Reverse Stock Split
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result of its one-for-fifteen reverse stock split which became effective at 5:00 p.m. Eastern Time on November 20, 2020, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") effective with the open of the market today, Monday, November 23, 2020. HTG's common stock will continue to trade under the ticker symbol "HTGM."
GlobeNewswire · 11/23 13:00
HTG Announces One-for-Fifteen Reverse Stock Split
TUCSON, Ariz., Nov. 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result of its one-for-fifteen reverse stock split which became effective at 5:00 p.m. Eastern Time on November 20, 2020, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) effective with the open of the market today, Monday, November 23, 2020. HTG’s common stock will continue to trade under the ticker symbol “HTGM.” As a result of the reverse stock split, each fifteen pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.  Stockholders of record will receive information regarding their share ownership from HTG’s transfer agent, American Stock Transfer & Trust Company, LLC (“AST”). AST can be reached at (877) 248-6417 or (718) 921-8337. For additional information regarding the reverse stock split, please refer to HTG’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 19, 2020.About HTG: HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.Contact: Ashley R. Robinson LifeSci Advisors, LLC Phone: (617) 430-7577 Email: arr@lifesciadvisors.com
GlobeNewswire · 11/23 13:00
Newsflash: HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analysts Have Been Trimming Their Revenue Forecasts
The latest analyst coverage could presage a bad day for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), with the...
Simply Wall St. · 11/15 13:32
HTG Molecular Diagnostics Reports Third Quarter 2020 Results
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended September 30, 2020.
GlobeNewswire · 11/10 21:01
HTG Molecular Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 10, 2020 / HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 10, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/10 19:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTGM. Analyze the recent business situations of HTG Molecular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTGM stock price target is 12.75 with a high estimate of 15.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 67
Institutional Holdings: 6.29M
% Owned: 132.68%
Shares Outstanding: 4.74M
TypeInstitutionsShares
Increased
9
135.09K
New
9
76.32K
Decreased
6
259.02K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.17%
Healthcare Equipment & Supplies
+1.33%
Key Executives
Chairman/Executive Director
Timothy Johnson
President/Chief Executive Officer/Director
John Lubniewski
Chief Financial Officer/Senior Vice President/Treasurer/Secretary
Shaun McMeans
Senior Vice President
Byron Lawson
Lead Director/Independent Director
Ann Hanham
Independent Director
Harry George
Independent Director
Michelle Griffin
Independent Director
Donnie Hardison
Independent Director
James LaFrance
Independent Director
Lee McCracken
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HTGM
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of HTG Molecular Diagnostics Inc stock information, including NASDAQ:HTGM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTGM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTGM stock methods without spending real money on the virtual paper trading platform.